AdaptHealth Corp. (NASDAQ:AHCO) Given Consensus Rating of “Hold” by Analysts

AdaptHealth Corp. (NASDAQ:AHCO) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $12.10.

AHCO has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $13.00 target price on shares of AdaptHealth in a report on Monday, March 4th. Truist Financial lifted their price objective on shares of AdaptHealth from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Jefferies Financial Group downgraded shares of AdaptHealth from a “buy” rating to a “hold” rating and lowered their target price for the company from $14.50 to $8.00 in a research note on Monday, January 8th. Finally, UBS Group increased their target price on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th.

AdaptHealth Trading Down 0.9 %

AHCO opened at $10.26 on Monday. AdaptHealth has a fifty-two week low of $6.37 and a fifty-two week high of $15.37. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -1.93, a price-to-earnings-growth ratio of 0.66 and a beta of 1.06. The company has a debt-to-equity ratio of 1.44, a current ratio of 1.21 and a quick ratio of 1.00. The firm has a 50 day simple moving average of $10.27 and a 200 day simple moving average of $8.50.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The company had revenue of $858.23 million for the quarter, compared to the consensus estimate of $825.94 million. On average, sell-side analysts anticipate that AdaptHealth will post 0.88 earnings per share for the current year.

Insider Transactions at AdaptHealth

In other news, major shareholder James E. Flynn sold 52,487 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $10.93, for a total value of $573,682.91. Following the sale, the insider now owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other AdaptHealth news, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the transaction, the insider now owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder James E. Flynn sold 52,487 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $10.93, for a total value of $573,682.91. Following the completion of the sale, the insider now directly owns 11,826,376 shares of the company’s stock, valued at approximately $129,262,289.68. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.

Institutional Trading of AdaptHealth

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of AdaptHealth by 197.1% in the first quarter. GAMMA Investing LLC now owns 2,537 shares of the company’s stock valued at $29,000 after buying an additional 1,683 shares during the last quarter. Oak Thistle LLC bought a new stake in AdaptHealth in the 3rd quarter valued at $94,000. Campbell & CO Investment Adviser LLC bought a new position in AdaptHealth during the third quarter worth $100,000. Raymond James & Associates acquired a new position in shares of AdaptHealth in the third quarter valued at $101,000. Finally, Everence Capital Management Inc. acquired a new position in shares of AdaptHealth in the fourth quarter valued at $102,000. 82.67% of the stock is owned by institutional investors.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.